TICKERNERD
Menu
LRMRLRMRHealthcare · Biotechnology

LRMR Stock Forecast: Larimar Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$3.78
−3.57% on the day

The 11 Wall Street analysts covering Larimar Therapeutics, Inc. hold a median 12-month price target of $13 — +230.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$407.2M
Ticker Nerd rank
30 / 100
Median analyst target
$13
Analysts covering
11
Revenue$0.0
Operating income−$34.4M
Net income−$32.8M
Free cash flow−$44.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
−13.3%
YTD
−0.8%
1Y
−3.8%
From 52W high
−36.5%
From 52W low
+34.5%
$2.81
$5.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LRMR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Larimar Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
72
Accruals
68
Size
56
Momentum
49
Volatility
39
Value
31
Issuance
23
Growth
22
Quality
17

Revisions (72): Analysts have, on balance, been raising their forecasts.

Quality (17): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LRMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LRMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26LRMRHigh $26Median $13Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $5Median $13High $26

The green dot is the last close — the median target sits +230.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026WedbushMaintainsOutperform$12 → $11
2 July 2026HC Wainwright & Co.AssumesBuy$10
30 June 2026BairdMaintainsOutperform$7.00 → $5.00
30 June 2026BairdMaintainsOutperform—
27 May 2026JP MorganInitiatesOverweight—
18 May 2026WedbushMaintainsOutperform—
20 Mar 2026WedbushMaintainsOutperform—
3 Mar 2026WedbushMaintainsOutperform—
25 Feb 2026CitigroupMaintainsBuy—
25 Feb 2026WedbushReiteratesOutperform—
2 Oct 2025OppenheimerMaintainsOutperform—
30 Sept 2025BairdMaintainsOutperform—
30 Sept 2025WedbushMaintainsOutperform—
19 Aug 2025JMP SecuritiesReiteratesMarket Outperform—
15 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
25 June 2025GuggenheimReiteratesBuy—
24 June 2025GuggenheimReiteratesBuy—
24 June 2025WedbushMaintainsOutperform—
25 Mar 2025BairdMaintainsOutperform—
25 Mar 2025GuggenheimReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LRMR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LRMR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Larimar Therapeutics, Inc. returned −3.8% against +17.0% for the S&P 500, dividends included.

LRMR vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26LRMRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LRMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Larimar Therapeutics, Inc. (LRMR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
3.2×

Cheaper than 31% of US stocks

EV / EBITDA
−1.4×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−139.6%

Higher than 10% of US stocks

Return on assets
−71.0%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Larimar Therapeutics, Inc. (LRMR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Larimar Therapeutics, Inc. has a market value of $407.2M and an enterprise value of $257.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$172.6M.

  • Diluted earnings per share, trailing twelve months: $−1.95.

  • Free cash flow in the twelve months to 30 June 2026: −$156.1M.

  • Shares outstanding: 103.9M.

  • Trailing P/E: −1.7×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Larimar Therapeutics, Inc. employs 71 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

LRMR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LRMRLarimar Therapeutics, Inc.$407.2M
30
EDITEditas Medicine, Inc.$414.3M
78
BNTCBenitec Biopharma, Inc.$410.3M
42
ARCTArcturus Therapeutics Holdings, Inc.$418.5M
66
RZLTRezolute, Inc.$403.8M
33
AVIRAtea Pharmaceuticals, Inc.$425.9M
67
BBOTBridgebio Oncology Therapeutics, Inc.$396.9M
9

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Larimar Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LRMR news & analysis

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

Zacks Investment Research · 14 Sept 2026positive

Zacks Investment Research identified Larimar Therapeutics (LRMR) among five small drug stocks it says could offer significant upside as biotech sentiment improves, citing the company's catalysts and differentiated pipeline.

Why it matters — This signals that a financial research firm sees LRMR as well-positioned to benefit from improving biotech sentiment, highlighting its pipeline and catalyst potential.

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

GlobeNewsWire · 4 Aug 2026neutral

Larimar Therapeutics reported its second quarter 2026 operating and financial results in a business update on August 4, 2026. The clinical-stage biotechnology company, which focuses on treatments for rare diseases, disclosed its quarterly financial and operational progress.

Why it matters — LRMR watchers would care because the quarterly update provides insight into the company's financial health and operational status, including its progress in developing treatments for complex rare diseases.

FAQ

Frequently asked questions about LRMR stock

What is the LRMR stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Larimar Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $5 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LRMR stock a buy right now?

Of the 11 analysts covering Larimar Therapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Larimar Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LRMR?

As at 12 Sept 2026, Larimar Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).

Will LRMR stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +230.7% from the last close, and Ticker Nerd's factor model ranks Larimar Therapeutics, Inc. 30 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LRMR stock forecast for 2030?

No analyst covering Larimar Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LRMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $26 over the next 12 months.

How has LRMR stock performed over the past year?

Larimar Therapeutics, Inc. returned -3.8% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Larimar Therapeutics, Inc. do?

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia.

What is the latest news on LRMR?

The most recent item we track (Zacks Investment Research, 14 Sept 2026): "5 Small Drug Stocks Poised to Benefit From a Biotech Recovery". Zacks Investment Research identified Larimar Therapeutics (LRMR) among five small drug stocks it says could offer significant upside as biotech sentiment improves, citing the company's catalysts and differentiated pipeline.

Company

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with an emphasis on Friedreich’s ataxia. The company’s core program is nomlabofusp, a protein replacement therapy designed to deliver frataxin inside cells and address the underlying biology of this inherited disorder. Larimar’s work centers on its proprietary intracellular delivery platform, which is intended to support the development of additional therapies for rare conditions caused by missing or deficient proteins. The company operates as a focused research and development organization, advancing clinical programs and related manufacturing, development, and regulatory activities through external partners. Larimar Therapeutics is based in Bala Cynwyd, Pennsylvania, and plays a specialized role in the rare-disease biopharmaceutical market by pursuing targeted treatments for patients with limited therapeutic options.

CEO Dr. Carole S. Ben-Maimon M.D. · 71 employees · United States · https://www.larimartx.com